Literature DB >> 31458141

Ru(II)/Ir(III)-Catalyzed C-H Bond Activation/Annulation of Cyclic Amides with 1,3-Diketone-2-diazo Compounds: Facile Access to 8H-Isoquinolino[1,2-b]quinazolin-8-ones and Phthalazino[2,3-a]cinnoline-8,13-diones.

Panyuan Cai1, Enshen Zhang1, Yinsong Wu1, Taibei Fang1, Qianqian Li1, Chen Yang1, Jian Wang1, Yongjia Shang1.   

Abstract

Efficient access to 8H-isoquinolino[1,2-b]quinazolin-8-ones and phthalazino[2,3-a]cinnoline-8,13-diones through cyclic amide-directed Ru(II)/Ir(III)-catalyzed C-H bond activation, has been developed. Consecutive C-H bond activation, carbene insertion, and condensation annulation processes were realized, affording 8H-isoquinolino[1,2-b]quinazolin-8-one and phthalazino[2,3-a]cinnoline-8,13-dione derivatives in good-to-excellent yields under mild conditions, with H2O and N2 being generated as the only byproducts.

Entities:  

Year:  2018        PMID: 31458141      PMCID: PMC6644029          DOI: 10.1021/acsomega.8b01930

Source DB:  PubMed          Journal:  ACS Omega        ISSN: 2470-1343


Introduction

As poly cyclic nitrogen-containing heterocycles, 8H-isoquinolino[1,2-b]quinazolin-8-ones and phthalazino[2,3-a]cinnoline-8,13-diones are ubiquitous in many bioactive synthetic compounds as well as natural products (Scheme ). For example, compounds A and B as shown in Scheme were proved to have efficient antitumor activities.[1,2] Poly cyclic nitrogen-containing heterocycles were also commonly applied in anticonvulsant,[3−5] anti-inflammatory,[6] antiallergy,[7,8] antimicrobial,[9] cardiotonic,[10] and cell imaging[11,12] research. Scaffold of 11H-pyrido[2,1-b]quinazolin-11-one H was found in many natural products[13] (Scheme ). Traditional synthesis of such polycyclic compounds suffered from multiple steps and harsh reaction conditions. Thus, developing general and efficient approaches for the construction of 8H-isoquinolino[1,2-b]quinazolin-8-one and phthalazino[2,3-a]cinnoline-8,13-dione derivatives attracted a lot of efforts. For example, Peng and Cui developed ruthenium and palladium catalyzed directed C–H bond activation of 2-phenylquinazolin-4(3H)-ones and alkyne insertion annulations for the synthesis of 8H-isoquinolino[1,2-b]quinazolin-8-ones, respectively (Scheme ).[14,15] Synthesis of phthalazino[2,3-a]cinnoline-8,13-diones was independently reported by Gandhi and Perumal via ruthenium and rhodium catalyzed alkyne insertion reactions with 2-phenyl-2,3-dihydrophthalazine-1,4-diones.[16,17]
Scheme 1

Representative Bioactive Molecules

Scheme 2

Transition-Metal Catalyzed C–H Activation Reactions of 2-Phenylquinazolin-4(3H)-ones and 2-Phenyl-2,3-dihydrophthalazine-1,4-diones

Transition-metal catalyzed C–H bond activation reactions have been a long-term research interest of organic chemists for the construction of new C–C and C–X (X = N, O, S et al.) bonds because of the environmental benignity and simple operation. As a C1 building block, carbene has attracted much attention based on its high and diverse reaction reactivities.[18−21] 1,3-Diketone-2-diazo compounds can not only react as a C1 synthon but also be used as an equivalent of alkynes, undergoing formal C2 insertion reaction with cyclic compounds being constructed.[22] However, compared with alkynes, 1,3-diketone-2-diazo compounds have their unique characteristics. For instance, no additional oxidants, to which lots of substrates cannot tolerate, were needed. Additionally, cyclic 1,3-diketone-2-diazo compounds have their priorities because of the instability of cyclic alkynes.[23] Herein, we report facile access to 8H-isoquinolino[1,2-b]quinazolin-8-ones and phthalazino[2,3-a]cinnoline-8,13-diones via ruthenium and iridium catalyzed C–H bond activation/annulation reaction of cyclic amide derivatives. In these reactions, both cyclic and acyclic 1,3-diketone-2-diazo compounds could be transformed to corresponding products smoothly in good to excellent yields with H2O and N2 as the only byproducts.

Results and Discussion

The reaction was initiated with 2-(p-tolyl)quinazolin-4(3H)-one (1a) and 2-diazo-5-methylcyclohexane-1,3-dione (2a) as model substrates with the catalysis of (RhCp*Cl2)2/AgNTf2 at 90 °C (Table , entry 1). To our delight, the desired product 2,6-dimethyl-2,3-dihydro-4H-quinazolino[3,2-f]phenanthridine-4,14(1H)-dione (3a) was obtained in 58% yield. Screening of catalysts revealed that 3 mol % of [(p-cymene)RuCl2]2 gave the best result (entries 2–5). Further investigation of additives and solvents showed lower efficacy (entries 6–11). In addition, no better results were found at lower or higher reaction temperatures (80 and 100 °C).
Table 1

Optimization of Reaction Conditionsa

entrycatalyst (mol %)additive (30 mol %)solventtemp. (°C)time (min)yield (%)b
1(RhCp*Cl2)2 (3)AgNTf2t-BuOH904058
2(IrCp*Cl2)2 (3)AgNTf2t-BuOH904047
3[(p-cymene)RuCl2]2 (3)AgNTf2t-BuOH904073
4[(p-cymene)RuCl2]2 (1)AgNTf2t-BuOH904049
5[(p-cymene)RuCl2]2 (5)AgNTf2t-BuOH904066
6[(p-cymene)RuCl2]2 (3)AgSbF6t-BuOH904051
7[(p-cymene)RuCl2]2 (3)CsOAct-BuOH904040
8[(p-cymene)RuCl2]2 (3)AgNTf2DMF904058
9[(p-cymene)RuCl2]2 (3)AgNTf2DCE904040
10[(p-cymene)RuCl2]2 (3)AgNTf2toluene904031
11[(p-cymene)RuCl2]2 (3)AgNTf2t-AmOH904066
12[(p-cymene)RuCl2]2 (3)AgNTf2t-BuOH804041
13[(p-cymene)RuCl2]2 (3)AgNTf2t-BuOH1004029

Reaction conditions: 1a (0.50 mmol), 2a (0.5 mmol) in the presence of catalyst/additive in 5 mL of solvent under air.

Isolated yields.

Reaction conditions: 1a (0.50 mmol), 2a (0.5 mmol) in the presence of catalyst/additive in 5 mL of solvent under air. Isolated yields. With the optimized conditions in hand, the substrate scope of 2-phenylquinazolin-4(3H)-one derivatives were investigated first (Scheme ). Substituents such as OMe, OBn, Br, Bu, Cl, and OH on the aromatic rings were well tolerated under the optimal conditions, generating the corresponding products in moderate-to-good yields (3a–3i). It is worthy to note that the substrate with the hydroxyl group which is intolerable under many reaction conditions could be transformed to product 3i in an acceptable 50% yield. When phenyl, dimethyl, or nonsubstituted cyclic diazo compounds worked as the reactants, products 3j–3l were obtained in moderate yields. Meanwhile, heterocyclic C–H bond activation was realized to generate 3m in 68% yield. However, acyclic 1,3-diketone-2-diazo compounds failed to suffer the reaction conditions.
Scheme 3

Scope of the Reaction with 2-Phenylquinazolin-4(3H)-ones

Reaction conditions: 1 (0.50 mmol), 2 (0.5 mmol), [(p-cymene)RuCl2]2 (3 mol %), AgNTf2 (30 mol %), 5 mL of BuOH, 90 °C. Isolated yields.

Scope of the Reaction with 2-Phenylquinazolin-4(3H)-ones

Reaction conditions: 1 (0.50 mmol), 2 (0.5 mmol), [(p-cymene)RuCl2]2 (3 mol %), AgNTf2 (30 mol %), 5 mL of BuOH, 90 °C. Isolated yields. Other types of cyclic amide-directed C–H bond activations were further investigated with easily accessible 2-phenyl-2,3-dihydrophthalazine-1,4-dione (4a) and 2-diazo-5,5-dimethylcyclohexane-1,3-dione (2b) as model substrates. With the above optimized catalytic system at a higher temperature of 100 °C, 2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5a) was generated in 60% yield (Table , entry 1). After optimization of the reaction conditions, the yield of 5a was increased to 93% under the condition of (IrCp*Cl2)2/AgSbF6 as catalyst in DCE at 100 °C (entry 3).
Table 2

Optimization of Reaction Conditions for Synthesis of 5aa

entrycatalyst (mol %)additive (mol %)solventtemp. (°C)time (h)yield (%)b
1[(p-cymene)RuCl2]2 (3)AgNTf2 (30)t-BuOH1001460
2(IrCp*Cl2)2 (1.5)AgSbF6 (20)DCE1001467
3(IrCp*Cl2)2 (2)AgSbF6 (20)DCE1001493
4(IrCp*Cl2)2 (2.5)AgSbF6 (20)DCE1001470
5(IrCp*Cl2)2 (2)AgSbF6 (10)DCE1001468
6(IrCp*Cl2)2 (2)AgSbF6 (30)DCE1001456
7(IrCp*Cl2)2 (2.5)AgSbF6 (20)acetone1001432
8(RhCp*Cl2)2 (2)AgSbF6 (30)THF1001410

Reaction conditions: 1a (0.50 mmol), 4a (0.5 mmol), catalyst/additive (as indicated in the table), 5 mL solvent, 14 h, nitrogen atmosphere.

Isolated yields.

Reaction conditions: 1a (0.50 mmol), 4a (0.5 mmol), catalyst/additive (as indicated in the table), 5 mL solvent, 14 h, nitrogen atmosphere. Isolated yields. Next, the scope of the reaction was investigated under the optimized conditions (Scheme ). Substrates with Me, Bu, F, Cl, and Br underwent the reaction efficiently with 2-diazo-5,5-dimethylcyclohexane-1,3-dione (2b), generating the corresponding products in good to excellent yields (5a–5i). Steric hindered ortho-substituted substrates could tolerate the reaction conditions, generating 5g and 5h in 81 and 82% yields, respectively. Diverse poly cyclic heterocycles were obtained in good yields when using monomethyl, phenyl, and nonsubstituted cyclic diazo compounds as the reaction partners (5j–5r). It is worthy to note that five-membered-cyclic and acyclic 1,3-carbonyl-2-diazo compounds tolerated the reaction conditions, generating the corresponding products 5s–5x in excellent yields.
Scheme 4

Scope of the Reaction with 2-Phenyl-2,3-dihydrophthalazine-1,4-diones

Reaction conditions: 4 (0.5 mmol), 2 (0.5 mmol), (IrCp*Cl2)2 (2 mol %), AgSbF6 (20 mol %), 5 mL of DCE, 100 °C. Isolated yields.

Scope of the Reaction with 2-Phenyl-2,3-dihydrophthalazine-1,4-diones

Reaction conditions: 4 (0.5 mmol), 2 (0.5 mmol), (IrCp*Cl2)2 (2 mol %), AgSbF6 (20 mol %), 5 mL of DCE, 100 °C. Isolated yields. On the basis of the reported transition-metal-catalyzed C–H bond activation/carbene insertion reactions[22,23,24] and the experiment results, a possible mechanism was proposed in Scheme . An active catalytic species I was generated by ligand exchange, which catalyzed C–H bond activation to form intermediate II. Carbene coordination and migratory insertion to intermediate II generated alkyl-ruthenium intermediate IV, which was then protonated to intermediate V. The catalyst I was released to complete the catalytic cycle. An isomerization/intramolecular condensation process of V took place spontaneously, affording the compound 3.
Scheme 5

Proposed Reaction Mechanism

Conclusion

In conclusion, we have developed an efficient and practical method for the synthesis of 8H-isoquinolino[1,2-b]quinazolin-8-one and phthalazino[2,3-a]cinnoline-8,13-dione derivatives via ruthenium and iridium catalyzed C–H bond activation reactions. Diverse nitrogen-containing poly cyclic compounds were synthesized effectively under mild conditions. The reaction proceeds through consecutive C–H bond activation, carbene insertion, and annulation reaction with water and N2 as the only byproducts, revealing the environmental benignity of this reaction.

Experimental Section

General Comments

Unless otherwise specified, all reagents and starting materials were purchased from commercial sources and used as received and the solvents were purified and dried using standard procedures. The chromatography solvents were of technical grade and distilled prior to use. Flash chromatography was performed using 200–300 mesh silica gel with the indicated solvent system according to standard techniques. The 1H and 13C NMR data were recorded on 300/500 and 75/125 MHz NMR spectrometers, unless otherwise specified. Chemical shifts (δ) in parts per million are reported relative to the residual signals of chloroform (7.26 ppm for 1H and 77.16 ppm for 13C), and all 13C NMR were recorded with proton broadband decoupling and indicated as 13C{1H} NMR. Multiplicities are described as s (singlet), d (doublet), t (triplet), q (quartet), or m (multiplet), and the coupling constants (J) are reported in hertz. HRMS analysis with a quadrupole time-of-flight mass spectrometer yielded ion mass/charge (m/z) ratios in atomic mass units. IR spectra were measured as dry films (KBr), and the peaks are reported in terms of wave number (cm–1).

Procedure A: The Synthesis of 8H-Isoquinolino[1,2-b]quinazolin-8-one Derivatives 3

To a solution of 2-(p-tolyl)quinazolin-4(3H)-one (0.5 mmol) and [(p-cymene)RuCl2]2 (3 mol %)/AgNTf2 (30 mol %) in t-BuOH (2 mL) at 90 °C was added portion wise a solution of 2-diazo-5-methylcyclohexane-1,3-dione (0.5 mmol). After being stirred for another 40 min, the mixture was cooled to room temperature. The reaction was quenched with water, and the mixture was extracted with DCM three times. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel to afford 2,6-dimethyl-2,3-dihydro-4H-quinazolino[3,2-f] phenanthridine-4,14(1H)-dione 3.

Procedure B: The Synthesis of Phthalazino[2,3-a]cinnoline-8,13-dione Derivatives 5

A mixture of cyclic 2-diazo-1,3-diketones 2 (0.5 mmol), 2-phenyl-2,3-dihydrophthalazine-1,4-dione 4 (0.5 mmol), [Cp*IrCl2]2 (2 mol %), and AgSbF6 (20 mol %) in DCE (2 mL) was heated in an oil bath at 100 °C for 14 h. Upon completion of the reaction, the mixture was cooled to room temperature. The residue was purified by flash column chromatography on silica gel (200–300 mesh) with ethyl acetate and petroleum ether (1:6–1:8, v/v) as the elution solvent to give the desired products 5.

2-Methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3a)

Yellow solid. 124 mg, 73% yield; mp: 221–223 °C; 1H NMR (500 MHz, CDCl3): δ 8.88 (s, 1H), 8.85–8.76 (m, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.86–7.77 (m, 2H), 7.47 (m, 1H), 7.40 (d, J = 8.0 Hz, 1H), 3.48 (dd, J = 18.5, 11.0 Hz, 1H), 3.37–3.18 (m, 1H), 2.80–2.77 (m, 1H), 2.53 (s, 3H), 2.49 (dd, J = 17.0, 13.0 Hz, 1H), 2.26–2.12 (br s, 1H), 1.16 (d, J = 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 198.3, 161.6, 149.3, 147.2, 146.1, 143.9, 135.3, 129.9, 129.7, 127.2, 27.1, 126.5, 126.4, 126.2, 119.8, 118.5, 105.0, 47.1, 39.1, 30.2, 22.5, 20. 6; IR(KBr) ν: 2912, 1693, 1664, 1595, 1546, 1323, 761 cm–1; HRMS (ESI) calcd for C22H18N2O2 [M + H]+, 343.1441; found, 343.1448.

2-Methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3b)

Yellow solid. 100 mg, 61% yield; mp: 218–220 °C; 1H NMR (300 MHz, CDCl3): δ 9.08 (d, J = 8.1 Hz, 1H), 8.97 (d, J = 7.8 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H), 7.86 (br s, 2H), 7.72 (t, J = 7.2 Hz, 1H), 7.60 (t, J = 7.2 Hz, 1H), 7.50 (dd, J = 9.6, 4.1 Hz, 1H), 3.50 (dd, J = 18.3, 10.8 Hz, 1H), 3.26 (d, J = 18.3 Hz, 1H), 2.79 (d, J = 16.8 Hz, 1H), 2.50 (dd, J = 16.5, 12.9 Hz, 1H), 2.22 (s, 1H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 198.1, 162.2, 149.8, 146.8, 146.5, 135.3, 132.6, 129.6, 128.4, 127.0, 127.0, 126.820, 126.4, 126.3, 120.1, 118.3, 47.4, 39.2, 30.0, 21.0; IR(KBr) ν: 2933, 1693, 1664, 1595, 1562, 1458, 1325, 1195, 765, 698 cm–1; HRMS (ESI) calcd for C21H16N2O2 [M + H]+, 329.1285; found, 329.1282.

6-Methoxy-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3c)

Yellow solid. 94 mg, 53% yield; mp: 207–209 °C; 1H NMR (300 MHz, C6D6): δ 9.03 (d, J = 8.7 Hz, 1H), 8.72 (s, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.83 (t, J = 7.2 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 9.0 Hz, 1H), 3.98 (s, 3H), 3.51 (dd, J = 18.3, 10.8 Hz, 1H), 3.26 (d, J = 17.7 Hz, 1H), 2.79 (d, J = 16.8 Hz, 1H), 2.64–2.39 (m, 1H), 2.22 (s, 1H), 1.18 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 198.2, 163.7, 162.0, 150.6, 147.1, 135.5, 131.9, 129.3, 127.1, 126.1, 126.0, 119.4, 118.1, 117.7, 108.4, 55.7, 47.4, 39.4, 30.0, 21.0; IR (KBr) ν: 2964, 1691, 1666, 1595, 1544, 1363, 1379, 1319, 1026, 771 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390; found, 359.1394.

6-Bromo-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3d)

Yellow solid. 70 mg, 35% yield; mp: 215–217 °C; 1H NMR (300 MHz, CDCl3): δ 9.30 (d, J = 1.5 Hz, 1H), 8.76 (d, J = 8.7 Hz, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.82 (q, J = 8.1 Hz, 2H), 7.66 (d, J = 8.7 Hz, 1H), 7.50 (t, J = 6.6 Hz, 1H), 3.48 (dd, J = 18.6, 10.8 Hz, 1H), 3.25 (d, J = 17.1 Hz, 1H), 2.77 (d, J = 16.5 Hz, 1H), 2.47 (dd, J = 16.8, 12.8 Hz, 1H), 2.20 (s, 1H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 197.6, 162.0, 151.2, 146.3, 146.3, 135.4, 131.7, 130.9, 129.2, 128.6, 128.1, 127.1, 127.0, 126.6, 125.6, 120.2, 117.1, 47.2, 39.3, 29.9, 21.0; IR (KBr) ν: 2953, 1703, 1666, 1585, 1546, 1394, 1319, 912, 831, 771, 698 cm–1; HRMS (ESI) calcd for C21H15BrN2O2 [M + H]+, 345.1234; found, 345.1239.

6-(Benzyloxy)-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3e)

Yellow solid. 98 mg, 46% yield; mp: 208–210 °C; 1H NMR (300 MHz, CDCl3): δ 8.90 (d, J = 8.7 Hz, 1H), 8.82 (d, J = 1.8 Hz, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 3.6 Hz, 2H), 7.65–7.08 (m, 7H), 5.24 (s, 2H), 3.50 (dd, J = 18.3, 10.7 Hz, 1H), 3.27 (d, J = 17.7 Hz, 1H), 2.79 (d, J = 15.9 Hz, 1H), 2.64–2.35 (m, 1H), 2.21 (s, 1H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 198.3, 178.3, 162.3, 150.8, 150.1, 148.1, 146.9, 136.3, 135.2, 131.5, 129.9, 129.0, 128.6, 128.2, 127.8, 127.0, 126.7, 125.7, 119.7, 117.0, 118.86, 109.3, 103.1, 70.2, 47.4, 39.4, 29.9, 20.9; IR (KBr) ν: 2922, 1693, 1674, 1600, 1541, 1498, 1379, 1325, 1242, 1014, 886, 771, 692 cm–1; HRMS (ESI) calcd for C28H22N2O3 [M + H]+, 435.1703; found, 435.1696.

6-(tert-Butyl)-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3f)

Yellow solid. 85 mg, 45% yield; mp: 173–175 °C; 1H NMR (300 MHz, CDCl3): δ 9.19 (d, J = 8.4 Hz, 1H), 8.88 (d, J = 8.7 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 13.5 Hz, 2H), 7.66 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 3.50 (dd, J = 18.3, 10.6 Hz, 1H), 3.26 (d, J = 18.0 Hz, 1H), 2.79 (d, J = 14.7 Hz, 1H), 2.66–2.36 (m, 1H), 2.22 (s, 1H), 1.45 (d, J = 9.9 Hz, 9H), 1.17 (d, J = 6.4 Hz, 3); 13C NMR (75 MHz, CDCl3): δ 198.3, 162.2, 156.4, 149.7, 146.9, 146.6, 135.2, 129.5, 127.0, 126.8, 126.2, 126.0, 124.3,122.9, 120, 118.6, 47.5, 39.2, 35.6, 31.2, 30.0, 20.9; IR (KBr) ν: 2958, 1703, 1670, 1593, 1546, 1465, 1373, 1259, 777, 729 cm–1; HRMS (ESI) calcd for C25H24rN2O2 [M + H]+, 385.1911; found, 385.1912.

12-Chloro-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3g)

Yellow solid. 112 mg, 63% yield; mp: 213–215 °C; 1H NMR (300 MHz, CDCl3): δ 9.07 (d, J = 8.1 Hz, 1H), 8.89 (d, J = 7.8 Hz, 1H), 8.23 (s, 1H), 7.89–7.64 (m, 3H), 7.58 (t, J = 7.5 Hz, 1H), 3.47 (dd, J = 18.3, 10.8 Hz, 1H), 3.22 (d, J = 17.1 Hz, 1H), 2.78 (d, J = 16.5 Hz, 1H), 2.49 (dd, J = 16.5, 12.9 Hz, 1H), 2.21 (s, 1H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 198.0, 161.2, 149.5, 145.1, 135.6, 132.7, 131.8, 129.5, 128.7, 128.4, 126.9, 126.7, 126.4, 126.2, 121.0, 118.5, 47.3, 39.1, 29.9, 20.9; IR (KBr) ν: 2958, 1697, 1670, 1595, 1562, 1544, 1463, 1322, 1296, 1064, 837, 771, 690 cm–1; HRMS (ESI) calcd for C21H15Cl N2O2 [M + H]+, 363.0895; found, 363.0895.

7-Chloro-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3h)

Yellow solid. 81 mg, 46% yield; mp: 220–222 °C; 1H NMR (300 MHz, CDCl3): δ 9.09–8.74 (m, 2H), 8.27 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 6.3 Hz, 2H), 7.49 (t, J = 6.3 Hz, 1H), 7.37–7.11 (m, 1H), 3.50 (dd, J = 18.3, 10.8 Hz, 1H), 3.26 (d, J = 18.3 Hz, 1H), 2.78 (d, J = 16.8 Hz, 1H), 2.60–2.35 (m, 1H), 2.21 (s, 1H), 1.17 (d, J = 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 197.7, 162.1, 152.5, 151.3, 146.3, 135.3, 129.8, 129.7, 127.1, 126.8, 126.3, 119.9, 116.7, 116.4, 112.8, 112.5, 47.2, 39.2, 29.9, 20.9; IR (KBr) ν: 2964, 1693, 1664, 1598, 1550, 1490, 1323, 771 cm–1; HRMS (ESI) calcd for C21H15Cl N2O2 [M + H]+, 363.0895; found, 363.0900.

8-Hydroxy-2-methyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3i)

Yellow solid. 85 mg, 50% yield; mp: 197–199 °C; 1H NMR (300 MHz, CDCl3): δ 15.01 (s, 1H), 8.51 (d, J = 8.1 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H), 7.84 (t, J = 7.5 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.62 (t, J = 8.1 Hz, 1H), 7.51 (t, J = 7.5 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 3.44 (dd, J = 18.3, 10.8 Hz, 1H), 3.18 (d, J = 17.1 Hz, 1H), 2.78 (d, J = 16.8 Hz, 1H), 2.48 (dd, J = 16.8, 12.6 Hz, 1H), 2.20 (s, 1H), 1.17 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 197.5, 161.1, 152.5, 150.0, 148.6, 143.8, 135.6, 134.9, 130.2, 127.3, 126.6, 125.0, 119.8, 119.4, 116.9, 116.5, 47.4, 39.0, 29.8, 20.9; IR (KBr) ν: 3419, 2958, 1708, 1664, 1598, 1544, 14 958, 1334, 1269, 810, 758, 696 cm–1; HRMS (ESI) calcd for C21H16N2O3 [M + H]+, 345.1234; found, 345.1233.

6-(Benzyloxy)-2-phenyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3j)

Yellow solid. 111 mg, 45% yield; mp: 217–219 °C; 1H NMR (300 MHz, CDCl3): δ 9.19 (d, J = 8.4 Hz, 1H), 8.90 (s, 1H), 8.21 (d, J = 7.5 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 7.90–7.73 (m, 1H), 7.64–7.17 (m, 10H), 5.28 (s, 2H), 4.02 (dd, J = 18.0, 11.5 Hz, 2H), 3.70–3.22 (m, 2H), 3.22–2.83 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 197.3 163.2 161.6, 149.9, 146.9, 141.9, 136.1, 135.7, 132.0, 129.7, 129.0, 128.7, 128.3, 127.8, 127.5, 127.2, 126.9, 126.2, 125.8, 119.1, 118.6, 109.5, 77.3, 77.0, 76.8, 70.4, 46.1, 40.5, 39.1; IR (KBr) ν: 2922, 1697, 1664, 1593, 1562, 1541, 1492, 1361, 1238, 1014, 771, 696 cm–1; HRMS (ESI) calcd for C33H24N2O3 [M + H]+, 497.1860; found, 497.1861.

6-(Benzyloxy)-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3k)

Yellow solid. 96 mg, 46% yield; mp: 169–171 °C; 1H NMR (300 MHz, CDCl3): δ 9.06 (d, J = 8.7 Hz, 1H), 8.82 (d, J = 2.1 Hz, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.83 (t, J = 7.5 Hz, 1H), 7.44 (m, 5H), 7.27 (d, J = 7.5 Hz, 2H), 5.25 (s, 2H), 3.52 (t, J = 5.7 Hz, 2H), 2.90–2.69 (m, 2H), 2.15–1.97 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 198.0, 162.7, 162.0, 151.3, 146.9, 136.2, 135.5, 129.4, 128.7, 128.3, 127.8, 127.1, 126.0, 118.2, 109.4, 105.0, 70.3, 39.5, 31.5, 22.5; IR (KBr) ν: 2933, 1693, 1660, 1550, 1367, 1301, 1236, 1010, 767, 692 cm–1; HRMS (ESI) calcd for C27H20N2O3 [M + H]+, 421.1547; found, 421.1541.

6-(Benzyloxy)-2,2-dimethyl-2,3-dihydro-1H-quinazolino[3,2-f]phenanthridine-4,14-dione (3l)

Yellow solid. 105 mg, 47% yield; mp: 165–167 °C; 1H NMR (300 MHz, CDCl3): δ 8.94 (d, J = 8.7 Hz, 1H), 8.81 (s, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.84 (d, J = 6.9 Hz, 2H), 7.44 (m, 5H), 7.26 (s, 1H), 5.25 (s, 2H), 3.41 (s, 2H), 2.64 (s, 2H), 1.09 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 198.4, 162.5, 149.28, 146.9, 146.6, 136.3, 136.2, 135.3, 135.0, 131.4, 129.1, 128.7, 128.2, 127.8, 127.1, 126.6, 125.8, 119.8, 119.5, 118.1, 117.3, 109.50, 70.3, 52.7, 44.5, 33.2, 27.9; IR (KBr) ν: 2954, 1697, 1674, 1600, 1564, 1496, 1471, 1377, 1323, 1271, 1176, 827, 773, 729, 692 cm–1; HRMS (ESI) calcd for C29H24N2O3 [M + H]+, 449.1860; found, 449.1857.

6-Methyl-6,7-dihydro-4H-thieno[2′,3′:3,4]quinolino[2,1-b]quinazoline-4,9(5H)-dione (3m)

Yellow solid. 113 mg, 68% yield; mp: 180–182 °C; 1H NMR (300 MHz, CDCl3): δ 8.44 (d, J = 4.8 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H), 7.92–7.61 (m, 3H), 7.46 (d, J = 3.3 Hz, 1H), 3.55 (dt, J = 29.1, 13.3 Hz, 2H), 2.78 (d, J = 16.5 Hz, 1H), 2.62–2.37 (m, 1H), 2.25 (s, 1H), 1.21 (d, J = 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 196.6, 162.3, 150.8, 144.7, 135.4, 133.8, 127.3, 126.8, 126.0, 125.7, 119.4, 117.8, 46.6, 39.1, 30.1, 21.1; IR (KBr) ν: 2958, 1703, 1674, 1589, 1539, 1471, 1394, 1317, 1112, 858, 767, 692 cm–1; HRMS (ESI) calcd for C19H14N2O2S [M + H]+, 335.0849; found, 335.0844.

2,2-Dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5a)

Yellow solid. 160 mg, 93% yield; mp: 190–192 °C; 1H NMR (500 MHz, CDCl3): δ 8.44 (d, J = 7.7 Hz, 1H), 8.31 (d, J = 7.7 Hz, 1H), 8.25–8.21 (m, 1H), 7.96–7.91 (m, 1H), 7.91–7.86 (m, 1H), 7.80–7.76 (m, 1H), 7.32–7.26 (m, 2H), 2.89 (s, 2H), 2.50 (s, 2H), 1.13 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 196.1, 167.0, 158.2, 152.6, 135.6, 135.1, 134.4, 129.0, 126.9, 122.7, 119.8, 118.1, 52.6, 41.2, 34.2, 28.6; IR (KBr) ν: 2975, 1691, 1669, 1599, 1379, 1298, 1248, 755, 724, 683 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390; found, 359.1397.

2,2,6-Trimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5b)

Yellow solid. 158 mg, 85% yield; mp: 207–209 °C; 1H NMR (500 MHz, CDCl3): δ 8.45–8.41 (m, 1H), 8.30 (dd, J = 7.7, 0.9 Hz, 1H), 8.03 (d, J = 1.4 Hz, 1H), 7.95–7.85 (m, 2H), 7.66 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.4, 1.4 Hz, 1H), 2.88 (s, 2H), 2.49 (s, 2H), 2.37 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 196.2, 158.2, 157.1, 152.5, 135.1, 129.1, 129.0, 128.9, 128.3, 127.6, 122.4, 119.6, 118.1, 52.6, 41.2, 34.2, 28.5, 21.7; IR (KBr) ν: 2958, 2373, 1685, 1671, 1374, 1304, 1251, 814, 733, 689 cm–1; HRMS (ESI) calcd for C23H20N2O3 [M + H]+, 373.1547; found, 373.1543.

6-(tert-Butyl)-2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5c)

Yellow solid. 155 mg, 75% yield; mp: 185–187 °C; 1H NMR (500 MHz, CDCl3): δ 8.44 (d, J = 7.7 Hz, 1H), 8.32–8.26 (m, 2H), 7.97–7.87 (m, 2H), 7.71 (d, J = 8.7 Hz, 1H), 7.32 (dd, J = 8.7, 2.2 Hz, 1H), 2.88 (s, 2H), 2.51 (s, 2H), 1.34 (s, 9H), 1.13 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 196.4, 158.2, 157.1, 152.4, 150.0, 135.1, 134.3, 133.1, 130.3, 129.1, 129.0, 128.3, 125.5, 124.3, 122.1, 119.2, 118.3, 52.7, 41.3, 35.2, 34.3, 31.6, 28.6; IR (KBr) ν: 2958, 2373, 1671, 1375, 1306, 1261, 1069, 687 cm–1; HRMS (ESI) calcd for C26H26N2O3 [M + H]+, 415.2016; found, 415.2022.

6-Chloro-2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5d)

Yellow solid. 157 mg, 83% yield; mp: 232–234 °C; 1H NMR (500 MHz, CDCl3): δ 8.42 (d, J = 7.7 Hz, 1H), 8.30 (d, J = 7.6 Hz, 1H), 8.28 (d, J = 2.3 Hz, 1H), 7.97–7.87 (m, 2H), 7.70 (d, J = 8.8 Hz, 1H), 7.25–7.22 (m, 1H), 2.87 (s, 2H), 2.49 (s, 2H), 1.12 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 195.7, 158.1, 157.2, 153.7, 135.3, 129.1, 129.0, 128.5, 128.2, 127.1, 124.3, 121.1, 116.9, 52.4, 41.2, 34.1, 28.5; IR (KBr) ν: 2970, 2373, 1671, 1596, 1485, 1374, 1343, 1301, 1067, 686 cm–1; HRMS (ESI) calcd for C22H17ClN2O3 [M + H]+, 393.1000; found: 393.0991.

2,2,7-Trimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5e)

Yellow solid. 164 mg, 88% yield; mp: 160–162 °C; 1H NMR (500 MHz, CDCl3): δ 8.45–8.39 (m, 1H), 8.32–8.25 (m, 1H), 8.13–8.07 (m, 1H), 7.95–7.83 (m, 2H), 7.60 (d, J = 1.1 Hz, 1H), 7.07 (dd, J = 8.1, 1.9 Hz, 1H), 2.86 (s, 2H), 2.48 (s, 2H), 2.33 (s, 3H), 1.11 (d, J = 1.8 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 196.3, 158.1, 157.3, 151.7, 138.8, 135.6, 135.0, 134.3, 127.1, 120.1, 119.9, 118.3, 52.6, 41.2, 34.3, 28.6, 21.9; IR (KBr) ν: 2953, 2379, 1674, 1607, 1376, 1301, 1251, 1170, 831, 689 cm–1; HRMS (ESI) calcd for C23H20N2O3 [M + H]+, 373.1547; found, 373.1544.

7-Bromo-2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5f)

Yellow solid. 175 mg, 80% yield; mp: 237–239 °C; 1H NMR (500 MHz, CDCl3): δ 8.41 (dd, J = 7.7, 1.1 Hz, 1H), 8.28 (dd, J = 7.7, 1.2 Hz, 1H), 8.11 (d, J = 8.6 Hz, 1H), 7.96–7.91 (m, 2H), 7.91–7.87 (m, 1H), 7.36 (dd, J = 8.6, 2.0 Hz, 1H), 2.85 (s, 2H), 2.48 (s, 2H), 1.12 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 195.9, 185.0, 158.0, 157.3, 153.0, 136.4, 135.3, 134.7, 128.5, 121.6, 117.5, 52.5, 41.3, 34.3, 28.6; IR (KBr) ν: 2964, 2368, 1680, 1658, 1368, 1296, 1243, 1173, 1070, 686 cm–1; HRMS (ESI) calcd for C22H17BrN2O3 [M + H]+, 437.0495; found, 437.0487.

2,2,8-Trimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5g)

Yellow solid. 151 mg, 81% yield; mp: 266–268 °C; 1H NMR (500 MHz, CDCl3): δ 8.38 (dd, J = 7.7, 1.1 Hz, 1H), 8.30 (dd, J = 7.7, 1.1 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.95–7.91 (m, 1H), 7.90–7.85 (m, 1H), 7.31–7.27 (m, 1H), 7.18 (d, J = 7.6 Hz, 1H), 3.50 (d, J = 18.2 Hz, 1H), 2.52 (d, J = 15.5 Hz, 1H), 2.40 (d, J = 15.5 Hz, 1H), 2.24 (d, J = 18.2 Hz, 1H), 2.01 (s, 3H), 1.16 (s, 3H), 1.07 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 196.1, 159.3, 157.1, 153.8, 135.5, 128.8, 128.7, 128.0, 125.5, 124.3, 122.4, 116.2, 52.4, 39.9, 33.4, 29.4, 27.9, 20.0; IR (KBr) ν: 2970, 1373, 1680, 1660, 1368, 1296, 1098, 786, 725, 686 cm–1; HRMS (ESI) calcd for C23H20N2O3 [M + H]+, 373.1547; found, 373.1550.

8-Fluoro-2,2-dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5h)

Yellow solid. 154 mg, 82% yield; mp: 218–220 °C; 1H NMR (500 MHz, CDCl3): δ 8.44–8.37 (m, 1H), 8.33–8.27 (m, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.97–7.85 (m, 2H), 7.35–7.27 (m, 1H), 7.12–7.03 (m, 1H), 3.52 (d, J = 18.3 Hz, 1H), 2.54 (d, J = 15.6 Hz, 1H), 2.41 (d, J = 15.6 Hz, 1H), 2.27 (d, J = 18.2 Hz, 1H), 1.17 (s, 3H), 1.07 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 195.7, 157.9 (d, J = 270 Hz), 154.4 (d, J = 26.3 Hz), 152.2, 135.5, 134.4, 129.6 (d, J = 28.8 Hz), 128.9 (d, J = 7.5 Hz), 126.7, 122.4, 121.3 (d, J = 11.3 Hz), 116.4 (d, J = 18.8 Hz), 115.9, 52.3, 40.5, 33.7, 29.8, 27.5; 19F NMR (470 MHz, CDCl3): δ −111.7; IR (KBr) ν: 2970, 2368, 1691, 1658, 1474, 1379, 1298, 795, 686 cm–1; HRMS (ESI) calcd for C22H17FN2O [M + H]+, 377.1296; found, 377.1300.

2,2-Dimethyl-2,3-dihydrobenzo[c]benzo[6,7]phthalazino[2,3-a]cinnoline-4,10,17(1H)-trione (5i)

Yellow solid. 167 mg, 82% yield; mp: 219–221 °C; 1H NMR (500 MHz, CDCl3): δ 8.98 (s, 1H), 8.87 (s, 1H), 8.23 (dd, J = 7.7, 1.6 Hz, 1H), 8.20–8.12 (m, 2H), 7.82–7.73 (m, 3H), 7.33–7.27 (m, 2H), 2.87 (s, 2H), 2.51 (s, 2H), 1.14 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 196.1, 158.8, 158.0, 153.1, 135.8, 135.7, 135.2, 130.7, 130.1, 128.4, 127.3, 126.9, 125.5, 124.9, 123.1, 120.2, 118.1, 52.6, 41.2, 34.2, 28.4; IR (KBr) ν: 2958, 2379, 1666, 1624, 1374, 1282, 1246, 1079, 772, 750 cm–1; HRMS (ESI) calcd for C26H20N2O3 [M + H]+, 409.1547; found, 409.1544.

2-Methyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5j)

Yellow solid. 142 mg, 82% yield; mp: 201–203 °C; 1H NMR (500 MHz, CDCl3): δ 8.43 (dd, J = 7.3, 2.3 Hz, 1H), 8.35–8.24 (m, 2H), 7.99–7.84 (m, 2H), 7.80–7.71 (m, 1H), 7.32–7.27 (m, 1H), 7.26–7.23 (m, 1H), 2.95 (d, J = 15.0 Hz, 1H), 2.80 (d, J = 21.9 Hz, 1H), 2.73–2.61 (m, 1H), 2.35 (dd, J = 16.9, 6.7 Hz, 2H), 1.12 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 196.2, 158.2, 157.2, 154.2, 135.5, 135.2, 134.4, 129.0, 127.0, 122.9, 119.9, 47.2, 35.6, 30.4, 21.6; IR (KBr) ν: 2958, 2925, 2368, 2340, 1685, 1674, 1320, 1297, 756, 687 cm–1; HRMS (ESI) calcd for C21H16N2O3 [M + H]+, 345.1234; found, 345.1238.

2,6-Dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5k)

Yellow solid. 170 mg, 95% yield; mp: 230–232 °C; 1H NMR (500 MHz, CDCl3): δ 8.41 (d, J = 7.8 Hz, 1H), 8.29 (d, J = 7.7 Hz, 1H), 8.07 (s, 1H), 7.93–7.84 (m, 2H), 7.64 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 8.9 Hz, 1H), 2.93 (d, J = 18.3 Hz, 1H), 2.85–2.72 (m, 1H), 2.69–2.62 (m, 1H), 2.35 (d, J = 10.2 Hz, 5H), 1.12 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 196.3, 158.3, 157.0, 153.9, 134.3, 129.2, 129.1, 128.9, 128.4, 127.6, 122.6, 119.7, 118.5, 47.2, 35.6, 30.5, 21.8, 21.6; IR (KBr) ν: 2958, 2368, 1688, 1663, 1381, 1325, 1297, 1258, 818, 687 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390; found, 359.1386.

6-Chloro-2-methyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5l)

Yellow solid. 153 mg, 81% yield; mp: 258–260 °C; 1H NMR (500 MHz, CDCl3): δ 8.40 (d, J = 7.6 Hz, 1H), 8.33–8.29 (m, 2H), 7.95–7.87 (m, 2H), 7.68 (d, J = 8.8 Hz, 1H), 7.23 (dd, J = 8.8, 2.3 Hz, 1H), 2.93 (d, J = 16.8 Hz, 1H), 2.79–2.76 (m, 1H), 2.70–2.64 (m, 1H), 2.37–2.30 (m, 2H), 1.12 (d, J = 5.7 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 195.7, 158.2, 157.2, 155.2, 134.5, 129.1, 129.0, 128.5, 128.3, 127.2, 124.5, 121.3, 117.3, 47.0, 35.7, 30.3, 21.5; IR (KBr) ν: 2953, 2362, 2340, 1688, 1669, 1318, 1293, 1240, 814 cm–1; HRMS (ESI) calcd for C21H15ClN2O3 [M + H]+, 379.0844; found, 379.0847.

6-Bromo-2-methyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5m)

Yellow solid. 180 mg, 85% yield; mp: 246–248 °C; 1H NMR (500 MHz, CDCl3): δ 8.47–8.29 (m, 3H), 7.95–7.87 (m, 2H), 7.65 (dd, J = 32.1, 8.8 Hz, 1H), 7.39–7.22 (m, 1H), 2.94 (d, J = 20.2 Hz, 1H), 2.86–2.73 (m, 1H), 2.73–2.61 (m, 1H), 2.42–2.29 (m, 2H), 1.11 (d, J = 5.8 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 195.7, 158.1, 157.2, 155.2, 135.3, 134.6, 129.0, 127.2, 121.5, 121.3, 46.9, 35.7, 30.3, 21.5; IR (KBr) ν: 3120, 2953, 2925, 2875, 2362, 2340, 1691, 1669, 1599, 1482, 1321, 1296, 1265, 689 cm–1; HRMS (ESI) calcd for C21H15BrN2O3 [M + H]+, 423.0339; found, 423.0334.

2,7-Dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5n)

Yellow solid. 170 mg, 95% yield; mp: 287–289 °C; 1H NMR (500 MHz, CDCl3): δ 8.42 (d, J = 7.3 Hz, 1H), 8.30 (d, J = 7.7 Hz, 1H), 8.16 (d, J = 8.2 Hz, 1H), 7.94–7.86 (m, 2H), 7.59 (s, 1H), 7.07 (dd, J = 8.2, 0.6 Hz, 1H), 2.91 (d, J = 18.1 Hz, 1H), 2.79 (d, J = 18.3 Hz, 1H), 2.69–2.62 (m, 1H), 2.38–2.31 (m, 5H), 1.11 (d, J = 5.2 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 196.3, 158.2, 157.3, 153.2, 138.8, 134.4, 127.2, 120.2, 120.1, 118.7, 47.2, 35.6, 30.5, 21.8, 21.6; IR (KBr) ν: 2958, 2380, 2346, 1683, 1675, 1318, 1296, 1239, 821, 688 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390; found, 359.1395.

7-Bromo-2-methyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5o)

Yellow solid. 171 mg, 81% yield; mp: 267–269 °C; 1H NMR (500 MHz, CDCl3): δ 8.43–8.41 (m, 1H), 8.31 (dd, J = 7.6, 1.2 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 7.96–7.88 (m, 3H), 7.38 (dd, J = 8.7, 2.0 Hz, 1H), 2.91 (d, J = 18.5 Hz, 1H), 2.78 (d, J = 28.9 Hz, 1H), 2.67 (d, J = 12.2 Hz, 1H), 2.36–2.32 (m, 2H), 1.12 (d, J = 6.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 195.9, 158.0, 157.3, 154.5, 136.4, 135.4, 134.7, 128.5, 121.8, 117.9, 47.1, 35.7, 30.4, 21.6; IR (KBr) ν: 2964, 2368, 1677, 1315, 1296, 1229, 783, 686 cm–1; HRMS (ESI) calcd for C21H15BrN2O3 [M + H]+, 423.0339; found, 423.0334.

2,8-Dimethyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5p)

Yellow solid. 152 mg, 85% yield; mp: 217–219 °C; 1H NMR (500 MHz, CDCl3): δ 8.39–8.36 (m, 1H), 8.30 (dd, J = 7.7, 0.8 Hz, 1H), 8.08 (dd, J = 18.7, 7.9 Hz, 1H), 7.93–7.91 (m, 1H), 7.88–7.85 (m, 1H), 7.30–7.27 (m, 1H), 7.17 (d, J = 7.4 Hz, 1H), 3.04 (dd, J = 17.9, 11.0 Hz, 1H), 2.69–2.60 (m, 2H), 2.40–2.34 (m, 2H), 2.01 (d, J = 7.5 Hz, 3H), 1.11 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 196.4, 159.8, 159.3, 157.3, 157.2, 155.5, 155.0, 134.1, 131.9, 130.9, 128.9, 128.7, 128.0, 124.4, 117.0, 116.7, 47.2, 35.7, 27.8, 21.9, 20.1; IR (KBr) ν: 2958, 2875, 1685, 1672, 1602, 1376, 1321, 1293, 1243, 781, 683 cm–1; HRMS (ESI) calcd for C22H18N2O3 [M + H]+, 359.1390; found, 359.1397.

2-Phenyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5q)

Yellow solid. 175 mg, 86% yield; mp: 188–190 °C; 1H NMR (500 MHz, CDCl3): δ 8.48–8.42 (m, 1H), 8.32 (dd, J = 7.6, 1.8 Hz, 1H), 8.26 (d, J = 8.1 Hz, 1H), 8.06–7.58 (m, 4H), 7.47–7.31 (m, 3H), 7.30–7.27 (m, 3H), 3.53–3.46 (m, 1H), 3.34–3.29 (m, 1H), 3.12 (d, J = 17.3 Hz, 1H), 2.96–2.86 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 195.5, 158.2, 157.3, 153.8, 142.4, 135.3, 134.4, 129.3, 128.6, 128.5, 127.8, 127.5, 127.1, 126.1, 125.2, 122.8, 119.9, 45.8, 40.8, 35.3; IR (KBr) ν: 3064, 2964, 2373, 2340, 1672, 1652, 1290, 1248, 733, 692 cm–1; HRMS (ESI) calcd for C26H18N2O3 [M + H]+, 407.1390; found, 407.1390.

6-Chloro-2-phenyl-2,3-dihydrobenzo[c]phthalazino[2,3-a]cinnoline-4,10,15(1H)-trione (5r)

Yellow solid. 179 mg, 81% yield; mp: 186–188 °C; 1H NMR (500 MHz, CDCl3): δ 8.40 (dd, J = 11.6, 5.0 Hz, 2H), 8.25 (d, J = 7.7 Hz, 1H), 7.95–7.91 (m, 2H), 7.71 (d, J = 8.9 Hz, 1H), 7.36–7.33 (m, 3H), 7.28–7.27 (m, 2H), 7.25 (s, 1H), 3.50–3.45 (m, 1H), 3.33–3.28 (m, 1H), 3.12 (d, J = 19.2 Hz, 1H), 2.90 (d, J = 9.5 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 195.0, 158.2, 157.2, 154.8, 142.2, 135.4, 134.6, 133.8, 132.7, 130.1, 129.3, 129.1, 128.6, 128.5, 127.9, 127.3, 127.1, 124.4, 121.3, 117.5, 45.7, 40.7, 35.4; IR (KBr) ν: 3070, 2379, 1694, 1672, 1596, 1374, 1298, 1251, 1184, 1070, 697 cm–1; HRMS (ESI) calcd for C26H17ClN2O3 [M + H]+, 441.1000; found, 441.1005.

1H-Cyclopenta[c]phthalazino[2,3-a]cinnoline-3,9,14(2H)-trione (5s)

Yellow solid. 136 mg, 86% yield; mp: 252–254 °C; 1H NMR (500 MHz, CDCl3): δ 8.46 (m, 1H), 8.35 (dd, J = 7.8, 1.1 Hz, 1H), 8.23 (dd, J = 7.2, 2.0 Hz, 1H), 7.97–7.94 (m, 1H), 7.92–7.89 (m, 1H), 7.79–7.77 (m, 1H), 7.32–7.27 (m, 2H), 3.46–3.36 (m, 2H), 2.73–2.61 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 196.1, 167.9, 165.9, 157.3, 156.4, 156.2, 153.9, 153.6, 128.5, 125.7, 123.0, 122.8, 122.7, 122.3, 122.2, 119.9, 119.8, 118.9, 118.5, 115.6, 115.4, 114.9, 114.7, 47.2, 35.6, 30.4, 21.6; IR (KBr) ν: 3075, 2925, 2379, 2340, 1702, 1674, 1630, 1602, 1382, 1326, 1304, 1251, 1062, 692 cm–1; HRMS (ESI) calcd for C19H12N2O3 [M + H]+, 317.0921; found, 317.0920.

Ethyl 6-Methyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5t)

Yellow solid. 146 mg, 84% yield; mp: 112–114 °C; 1H NMR (500 MHz, CDCl3): δ 8.44–8.37 (m, 1H), 8.34–8.26 (m, 1H), 7.93–7.78 (m, 3H), 7.32–7.27 (mz, 1H), 7.27–7.24 (m, 1H), 7.22–7.17 (m, 1H), 4.44–4.36 (m, 2H), 2.40 (d, J = 1.5 Hz, 3H), 1.41–1.36 (m, 3H); 13C NMR (125 MHz, CDCl3): δ 166.4, 157.6, 141.2, 134.4, 128.5, 123.9, 119.9, 119.4, 62.0, 17.9, 14.6; IR (KBr) ν: 2968, 2368, 1722, 1677, 1307, 1229, 1162, 775, 692 cm–1; HRMS (ESI) calcd for C20H16N2O4 [M + H]+, 349.1183; found, 349.1174.

Ethyl 3,6-Dimethyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5u)

Yellow solid. 154 mg, 85% yield; mp: 154–155 °C; 1H NMR (500 MHz, CDCl3): δ 8.39 (dd, J = 7.5, 0.8 Hz, 1H), 8.29 (dd, J = 8.3, 3.0 Hz, 1H), 7.92–7.80 (m, 2H), 7.72 (dd, J = 8.3, 2.7 Hz, 1H), 7.07 (s, 2H), 4.41 (q, J = 7.1 Hz, 2H), 2.38 (s, 3H), 2.33 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 166.5, 157.6, 157.5, 140.5, 136.7, 134.7, 134.2, 133.2, 130.1, 129.5, 129.2, 128.7, 128.2, 125.3, 123.6, 119.7, 119.5, 61.9, 21.6, 17.9, 14.6; IR (KBr) ν: 2981, 2932, 1733, 1659, 1607, 1319, 1232, 1177, 1047, 690 cm–1; HRMS (ESI) calcd for C21H18N2O4 [M + H]+, 363.1339; found, 363.1334.

Ethyl 3-Chloro-6-methyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5v)

Yellow solid. 170 mg, 89% yield; mp: 163–164 °C; 1H NMR (500 MHz, CDCl3): δ 8.39 (d, J = 7.0 Hz, 1H), 8.30 (dd, J = 7.5, 0.8 Hz, 1H), 7.94–7.84 (m, 2H), 7.76 (d, J = 8.9 Hz, 1H), 7.32 (d, J = 2.3 Hz, 1H), 7.22 (dd, J = 8.8, 2.3 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 2.42 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 165.8, 157.7, 157.6, 142.9, 134.9, 134.6, 134.0, 132.3, 129.9, 129.5, 128.9, 128.4, 128.3, 125.5, 125.0, 121.3, 118.1, 62.2, 18.0, 14.6; IR (KBr) ν: 2992, 2365, 2338, 1717, 1671, 1385, 1328, 1224, 1058, 688 cm–1; HRMS (ESI) calcd for C20H15ClN2O4 [M + H]+, 383.0793; found, 383.0795.

Ethyl 2,6-Dimethyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5w)

Yellow solid. 156 mg, 86% yield; mp: 122–123 °C; 1H NMR (500 MHz, CDCl3): δ 8.43–8.37 (m, 1H), 8.32–8.27 (m, 1H), 7.87 (dtd, J = 18.8, 7.4, 1.4 Hz, 2H), 7.66 (s, 1H), 7.19 (d, J = 8.0 Hz, 1H), 7.01 (dd, J = 8.0, 0.6 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 2.39 (s, 3H), 2.33 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 166.5, 157.7, 157.6, 140.2, 138.9, 135.7, 134.6, 134.4, 130.1, 129.6, 128.7, 128.2, 127.7, 124.9, 121.2, 120.1, 119.6, 61.9, 21.9, 17.8, 14.6; IR (KBr) ν: 2984, 2934, 2355, 2344, 1719, 1667, 1313, 1234, 1058, 688 cm–1; HRMS (ESI) calcd for C21H18N2O4 [M + H]+: 363.1339; found, 363.1337.

Ethyl 2-Bromo-6-methyl-8,13-dioxo-8,13-dihydrophthalazino[2,3-a]cinnoline-5-carboxylate (5x)

Yellow solid. 196 mg, 92% yield; mp: 182–183 °C; 1H NMR (500 MHz, CDCl3): δ 8.39 (d, J = 7.4 Hz, 1H), 8.32–8.26 (m, 1H), 8.00 (d, J = 1.7 Hz, 1H), 7.93–7.83 (m, 2H), 7.32 (dd, J = 8.5, 1.7 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 2.39 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 165.9, 157.7, 157.5, 142.2, 136.6, 134.9, 134.7, 129.9, 129.8, 129.5, 128.9, 128.4, 126.4, 122.9, 122.8, 121.9, 118.7, 62.1, 18.0, 17.9, 14.6; IR (KBr) ν: 2987, 2360, 2338, 1719, 1671, 1317, 1238, 1053, 804, 690 cm–1; HRMS (ESI) calcd for C20H15BrN2O4 [M + H]+, 427.0288; found, 427.0293.
  26 in total

Review 1.  Modern Organic Synthesis with α-Diazocarbonyl Compounds.

Authors:  Alan Ford; Hugues Miel; Aoife Ring; Catherine N Slattery; Anita R Maguire; M Anthony McKervey
Journal:  Chem Rev       Date:  2015-08-18       Impact factor: 60.622

2.  Ruthenium(II)-catalyzed C-H bond activation and functionalization.

Authors:  Percia Beatrice Arockiam; Christian Bruneau; Pierre H Dixneuf
Journal:  Chem Rev       Date:  2012-08-31       Impact factor: 60.622

3.  New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.

Authors:  J Bartroli; E Turmo; M Algueró; E Boncompte; M L Vericat; L Conte; J Ramis; M Merlos; J García-Rafanell; J Forn
Journal:  J Med Chem       Date:  1998-05-21       Impact factor: 7.446

4.  Cross-coupling/annulations of quinazolones with alkynes for access to fused polycyclic heteroarenes under mild conditions.

Authors:  Hui Lu; Qin Yang; Yirong Zhou; Yanqin Guo; Zhihong Deng; Qiuping Ding; Yiyuan Peng
Journal:  Org Biomol Chem       Date:  2013-12-16       Impact factor: 3.876

5.  Rhodium-catalyzed C-H activation of 3-(indolin-1-yl)-3-oxopropanenitriles with diazo compounds and tandem cyclization leading to hydrogenated azepino[3,2,1-hi]indoles.

Authors:  Tao Zhou; Bin Li; Baiquan Wang
Journal:  Chem Commun (Camb)       Date:  2016-12-01       Impact factor: 6.222

6.  Access to Spiroindolines and Spirodihydrobenzofurans via Pd-Catalyzed Domino Heck Spiroyclization through C-H Activation and Carbene Insertion.

Authors:  Jian-Guo Liu; Wen-Wen Chen; Chang-Xue Gu; Bin Xu; Ming-Hua Xu
Journal:  Org Lett       Date:  2018-04-19       Impact factor: 6.005

7.  Synthesis of Naphthoquinolizinones through Rh(III)-Catalyzed Double C(sp2)-H Bond Carbenoid Insertion and Annulation of 2-Aryl-3-cyanopyridines with α-Diazo Carbonyl Compounds.

Authors:  Beibei Zhang; Bin Li; Xinying Zhang; Xuesen Fan
Journal:  Org Lett       Date:  2017-04-24       Impact factor: 6.005

8.  Expedient synthesis of new cinnoline diones by Ru-catalyzed regioselective unexpected deoxygenation-oxidative annulation of propargyl alcohols with phthalazinones and pyridazinones.

Authors:  Subramani Rajkumar; S Antony Savarimuthu; Rajendran Senthil Kumaran; C M Nagaraja; Thirumanavelan Gandhi
Journal:  Chem Commun (Camb)       Date:  2016-01-07       Impact factor: 6.222

9.  Synthesis and anticonvulsant activity of some new 2-substituted 3-aryl-4(3H)-quinazolinones.

Authors:  J F Wolfe; T L Rathman; M C Sleevi; J A Campbell; T D Greenwood
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

10.  Additive-Driven Rhodium-Catalyzed [4+1]/[4+2] Annulations of N-Arylphthalazine-1,4-dione with α-Diazo Carbonyl Compounds.

Authors:  Pidiyara Karishma; Chikkagundagal K Mahesha; Devesh S Agarwal; Sanjay K Mandal; Rajeev Sakhuja
Journal:  J Org Chem       Date:  2018-09-18       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.